Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells

Autores
Liu, K.; Idoyaga, J.; Charalambous, A.; Fujii, S.-I.; Bonito, A.; Mordoh, J.; Wainstok, R.; Bai, X.-F.; Liu, Y.; Steinman, R.M.
Año de publicación
2005
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
If irradiated tumor cells could be rendered immunogenic, they would provide a safe, broad, and patient-specific array of antigens for immunotherapies. Prior approaches have emphasized genetic transduction of live tumor cells to express cytokines, costimulators, and surrogate foreign antigens. We asked if immunity could be achieved by delivering irradiated, major histocompatibility complex-negative plasmacytoma cells to maturing mouse dendritic cells (DCs) within lymphoid organs. Tumor cells injected intravenously (i.v.) were captured by splenic DCs, whereas subcutaneous (s.c.) injection led only to weak uptake in lymph node or spleen. The natural killer T (NKT) cells mobilizing glycolipid α-galactosyl ceramide, used to mature splenic DCs, served as an effective adjuvant to induce protective immunity. This adjuvant function was mimicked by a combination of poly IC and agonistic αCD40 antibody. The adjuvant glycolipid had to be coadministered with tumor cells i.v. rather than s.c. Specific resistance was generated both to a plasmacytoma and lymphoma. The resistance afforded by a single vaccination lasted >2 mo and required both CD4+ and CD8+ T cells. Mature tumor capturing DCs stimulated the differentiation of P1A tumor antigen-specific, CD8+ T cells and uniquely transferred tumor resistance to naive mice. Therefore, the access of dying tumor cells to DCs that are maturing to activated NKT cells efficiently induces long-lived adaptive resistance. JEM © The Rockefeller University Press.
Fil:Idoyaga, J. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina.
Fuente
J. Exp. Med. 2005;202(11):1507-1516
Materia
adjuvant
alpha CD40 antibody
alpha galactosylceramide
antibody
CD4 antigen
CD8 antigen
glycolipid
major histocompatibility antigen class 1
polyinosinic polycytidylic acid
tumor antigen
unclassified drug
animal cell
animal experiment
animal model
article
cell differentiation
cell maturation
controlled study
dendritic cell
drug delivery system
drug uptake
female
irradiation
lymph node
lymphoid organ
lymphoma
major histocompatibility complex
mouse
natural killer cell
nonhuman
plasmacytoma
priority journal
spleen
spleen cell
T lymphocyte
tumor immunity
tumor resistance
vaccination
Adjuvants, Immunologic
Animals
Antigen Presentation
Antigens, Neoplasm
Cancer Vaccines
CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes
Cell Differentiation
Dendritic Cells
Female
Gamma Rays
Immunotherapy, Active
Killer Cells, Natural
Lymph Nodes
Lymphocyte Activation
Lymphoma
Mice
Mice, Inbred BALB C
Neoplasm Transplantation
Neoplasms, Experimental
Plasmacytoma
Spleen
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by/2.5/ar
Repositorio
Biblioteca Digital (UBA-FCEN)
Institución
Universidad Nacional de Buenos Aires. Facultad de Ciencias Exactas y Naturales
OAI Identificador
paperaa:paper_00221007_v202_n11_p1507_Liu

id BDUBAFCEN_1d606abac1a16869a0358fa99d8fd169
oai_identifier_str paperaa:paper_00221007_v202_n11_p1507_Liu
network_acronym_str BDUBAFCEN
repository_id_str 1896
network_name_str Biblioteca Digital (UBA-FCEN)
spelling Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cellsLiu, K.Idoyaga, J.Charalambous, A.Fujii, S.-I.Bonito, A.Mordoh, J.Wainstok, R.Bai, X.-F.Liu, Y.Steinman, R.M.adjuvantalpha CD40 antibodyalpha galactosylceramideantibodyCD4 antigenCD8 antigenglycolipidmajor histocompatibility antigen class 1polyinosinic polycytidylic acidtumor antigenunclassified druganimal cellanimal experimentanimal modelarticlecell differentiationcell maturationcontrolled studydendritic celldrug delivery systemdrug uptakefemaleirradiationlymph nodelymphoid organlymphomamajor histocompatibility complexmousenatural killer cellnonhumanplasmacytomapriority journalspleenspleen cellT lymphocytetumor immunitytumor resistancevaccinationAdjuvants, ImmunologicAnimalsAntigen PresentationAntigens, NeoplasmCancer VaccinesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell DifferentiationDendritic CellsFemaleGamma RaysImmunotherapy, ActiveKiller Cells, NaturalLymph NodesLymphocyte ActivationLymphomaMiceMice, Inbred BALB CNeoplasm TransplantationNeoplasms, ExperimentalPlasmacytomaSpleenIf irradiated tumor cells could be rendered immunogenic, they would provide a safe, broad, and patient-specific array of antigens for immunotherapies. Prior approaches have emphasized genetic transduction of live tumor cells to express cytokines, costimulators, and surrogate foreign antigens. We asked if immunity could be achieved by delivering irradiated, major histocompatibility complex-negative plasmacytoma cells to maturing mouse dendritic cells (DCs) within lymphoid organs. Tumor cells injected intravenously (i.v.) were captured by splenic DCs, whereas subcutaneous (s.c.) injection led only to weak uptake in lymph node or spleen. The natural killer T (NKT) cells mobilizing glycolipid α-galactosyl ceramide, used to mature splenic DCs, served as an effective adjuvant to induce protective immunity. This adjuvant function was mimicked by a combination of poly IC and agonistic αCD40 antibody. The adjuvant glycolipid had to be coadministered with tumor cells i.v. rather than s.c. Specific resistance was generated both to a plasmacytoma and lymphoma. The resistance afforded by a single vaccination lasted >2 mo and required both CD4+ and CD8+ T cells. Mature tumor capturing DCs stimulated the differentiation of P1A tumor antigen-specific, CD8+ T cells and uniquely transferred tumor resistance to naive mice. Therefore, the access of dying tumor cells to DCs that are maturing to activated NKT cells efficiently induces long-lived adaptive resistance. JEM © The Rockefeller University Press.Fil:Idoyaga, J. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina.2005info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12110/paper_00221007_v202_n11_p1507_LiuJ. Exp. Med. 2005;202(11):1507-1516reponame:Biblioteca Digital (UBA-FCEN)instname:Universidad Nacional de Buenos Aires. Facultad de Ciencias Exactas y Naturalesinstacron:UBA-FCENenginfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/2.5/ar2025-10-16T09:30:20Zpaperaa:paper_00221007_v202_n11_p1507_LiuInstitucionalhttps://digital.bl.fcen.uba.ar/Universidad públicaNo correspondehttps://digital.bl.fcen.uba.ar/cgi-bin/oaiserver.cgiana@bl.fcen.uba.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:18962025-10-16 09:30:22.464Biblioteca Digital (UBA-FCEN) - Universidad Nacional de Buenos Aires. Facultad de Ciencias Exactas y Naturalesfalse
dc.title.none.fl_str_mv Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
title Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
spellingShingle Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
Liu, K.
adjuvant
alpha CD40 antibody
alpha galactosylceramide
antibody
CD4 antigen
CD8 antigen
glycolipid
major histocompatibility antigen class 1
polyinosinic polycytidylic acid
tumor antigen
unclassified drug
animal cell
animal experiment
animal model
article
cell differentiation
cell maturation
controlled study
dendritic cell
drug delivery system
drug uptake
female
irradiation
lymph node
lymphoid organ
lymphoma
major histocompatibility complex
mouse
natural killer cell
nonhuman
plasmacytoma
priority journal
spleen
spleen cell
T lymphocyte
tumor immunity
tumor resistance
vaccination
Adjuvants, Immunologic
Animals
Antigen Presentation
Antigens, Neoplasm
Cancer Vaccines
CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes
Cell Differentiation
Dendritic Cells
Female
Gamma Rays
Immunotherapy, Active
Killer Cells, Natural
Lymph Nodes
Lymphocyte Activation
Lymphoma
Mice
Mice, Inbred BALB C
Neoplasm Transplantation
Neoplasms, Experimental
Plasmacytoma
Spleen
title_short Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
title_full Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
title_fullStr Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
title_full_unstemmed Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
title_sort Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
dc.creator.none.fl_str_mv Liu, K.
Idoyaga, J.
Charalambous, A.
Fujii, S.-I.
Bonito, A.
Mordoh, J.
Wainstok, R.
Bai, X.-F.
Liu, Y.
Steinman, R.M.
author Liu, K.
author_facet Liu, K.
Idoyaga, J.
Charalambous, A.
Fujii, S.-I.
Bonito, A.
Mordoh, J.
Wainstok, R.
Bai, X.-F.
Liu, Y.
Steinman, R.M.
author_role author
author2 Idoyaga, J.
Charalambous, A.
Fujii, S.-I.
Bonito, A.
Mordoh, J.
Wainstok, R.
Bai, X.-F.
Liu, Y.
Steinman, R.M.
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv adjuvant
alpha CD40 antibody
alpha galactosylceramide
antibody
CD4 antigen
CD8 antigen
glycolipid
major histocompatibility antigen class 1
polyinosinic polycytidylic acid
tumor antigen
unclassified drug
animal cell
animal experiment
animal model
article
cell differentiation
cell maturation
controlled study
dendritic cell
drug delivery system
drug uptake
female
irradiation
lymph node
lymphoid organ
lymphoma
major histocompatibility complex
mouse
natural killer cell
nonhuman
plasmacytoma
priority journal
spleen
spleen cell
T lymphocyte
tumor immunity
tumor resistance
vaccination
Adjuvants, Immunologic
Animals
Antigen Presentation
Antigens, Neoplasm
Cancer Vaccines
CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes
Cell Differentiation
Dendritic Cells
Female
Gamma Rays
Immunotherapy, Active
Killer Cells, Natural
Lymph Nodes
Lymphocyte Activation
Lymphoma
Mice
Mice, Inbred BALB C
Neoplasm Transplantation
Neoplasms, Experimental
Plasmacytoma
Spleen
topic adjuvant
alpha CD40 antibody
alpha galactosylceramide
antibody
CD4 antigen
CD8 antigen
glycolipid
major histocompatibility antigen class 1
polyinosinic polycytidylic acid
tumor antigen
unclassified drug
animal cell
animal experiment
animal model
article
cell differentiation
cell maturation
controlled study
dendritic cell
drug delivery system
drug uptake
female
irradiation
lymph node
lymphoid organ
lymphoma
major histocompatibility complex
mouse
natural killer cell
nonhuman
plasmacytoma
priority journal
spleen
spleen cell
T lymphocyte
tumor immunity
tumor resistance
vaccination
Adjuvants, Immunologic
Animals
Antigen Presentation
Antigens, Neoplasm
Cancer Vaccines
CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes
Cell Differentiation
Dendritic Cells
Female
Gamma Rays
Immunotherapy, Active
Killer Cells, Natural
Lymph Nodes
Lymphocyte Activation
Lymphoma
Mice
Mice, Inbred BALB C
Neoplasm Transplantation
Neoplasms, Experimental
Plasmacytoma
Spleen
dc.description.none.fl_txt_mv If irradiated tumor cells could be rendered immunogenic, they would provide a safe, broad, and patient-specific array of antigens for immunotherapies. Prior approaches have emphasized genetic transduction of live tumor cells to express cytokines, costimulators, and surrogate foreign antigens. We asked if immunity could be achieved by delivering irradiated, major histocompatibility complex-negative plasmacytoma cells to maturing mouse dendritic cells (DCs) within lymphoid organs. Tumor cells injected intravenously (i.v.) were captured by splenic DCs, whereas subcutaneous (s.c.) injection led only to weak uptake in lymph node or spleen. The natural killer T (NKT) cells mobilizing glycolipid α-galactosyl ceramide, used to mature splenic DCs, served as an effective adjuvant to induce protective immunity. This adjuvant function was mimicked by a combination of poly IC and agonistic αCD40 antibody. The adjuvant glycolipid had to be coadministered with tumor cells i.v. rather than s.c. Specific resistance was generated both to a plasmacytoma and lymphoma. The resistance afforded by a single vaccination lasted >2 mo and required both CD4+ and CD8+ T cells. Mature tumor capturing DCs stimulated the differentiation of P1A tumor antigen-specific, CD8+ T cells and uniquely transferred tumor resistance to naive mice. Therefore, the access of dying tumor cells to DCs that are maturing to activated NKT cells efficiently induces long-lived adaptive resistance. JEM © The Rockefeller University Press.
Fil:Idoyaga, J. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina.
description If irradiated tumor cells could be rendered immunogenic, they would provide a safe, broad, and patient-specific array of antigens for immunotherapies. Prior approaches have emphasized genetic transduction of live tumor cells to express cytokines, costimulators, and surrogate foreign antigens. We asked if immunity could be achieved by delivering irradiated, major histocompatibility complex-negative plasmacytoma cells to maturing mouse dendritic cells (DCs) within lymphoid organs. Tumor cells injected intravenously (i.v.) were captured by splenic DCs, whereas subcutaneous (s.c.) injection led only to weak uptake in lymph node or spleen. The natural killer T (NKT) cells mobilizing glycolipid α-galactosyl ceramide, used to mature splenic DCs, served as an effective adjuvant to induce protective immunity. This adjuvant function was mimicked by a combination of poly IC and agonistic αCD40 antibody. The adjuvant glycolipid had to be coadministered with tumor cells i.v. rather than s.c. Specific resistance was generated both to a plasmacytoma and lymphoma. The resistance afforded by a single vaccination lasted >2 mo and required both CD4+ and CD8+ T cells. Mature tumor capturing DCs stimulated the differentiation of P1A tumor antigen-specific, CD8+ T cells and uniquely transferred tumor resistance to naive mice. Therefore, the access of dying tumor cells to DCs that are maturing to activated NKT cells efficiently induces long-lived adaptive resistance. JEM © The Rockefeller University Press.
publishDate 2005
dc.date.none.fl_str_mv 2005
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12110/paper_00221007_v202_n11_p1507_Liu
url http://hdl.handle.net/20.500.12110/paper_00221007_v202_n11_p1507_Liu
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/2.5/ar
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/2.5/ar
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv J. Exp. Med. 2005;202(11):1507-1516
reponame:Biblioteca Digital (UBA-FCEN)
instname:Universidad Nacional de Buenos Aires. Facultad de Ciencias Exactas y Naturales
instacron:UBA-FCEN
reponame_str Biblioteca Digital (UBA-FCEN)
collection Biblioteca Digital (UBA-FCEN)
instname_str Universidad Nacional de Buenos Aires. Facultad de Ciencias Exactas y Naturales
instacron_str UBA-FCEN
institution UBA-FCEN
repository.name.fl_str_mv Biblioteca Digital (UBA-FCEN) - Universidad Nacional de Buenos Aires. Facultad de Ciencias Exactas y Naturales
repository.mail.fl_str_mv ana@bl.fcen.uba.ar
_version_ 1846142849893007360
score 12.712165